Expert Outlines Treatment Approaches for Investigative Treatment in Advanced Prostate Cancer


Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.

New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

Researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, outlined the study methods in a recent interview with Pharmacy Times. Morris said trial participants received 200 mCi every 6 weeks for 4 cycles, with an option to increase to 6 cycles for patients who were responding. He added that the majority of the patients received 6 cycles.

Morris also emphasized how different the adverse events (AEs) are compared to AEs with taxane-based chemotherapy. Treatment with 177Lu-PSMA-617 does not result in neuropathy, changes in taste, alopecia, or neutropenic fever, Morris said.

Related Videos
Image credit: New Africa |
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages -
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder |
Image credit: Goffkein |
Image credit: Wild Awake |
Image credit: Dglimages |
Pharmacists checking inventory at pharmacy -- Image credit: Jacob Lund |
© 2024 MJH Life Sciences

All rights reserved.